Adicet Bio, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00JCXSJP3
ACET
Adicet Bio, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Adicet Bio, Inc.
ISIN
US0070021086
TICKER
ACET
MIC
XNAS
REUTERS
ACET.OQ
BLOOMBERG
ACET US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Sa., 16.11.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD...
Adicet Bio
Mi., 06.11.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024.
“Our commitment to delivering best-in-class gamma delta 1 T cell ...
Adicet Bio
Di., 05.11.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Wash...
Adicet Bio
Fr., 01.11.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November.
Details of the events are as follows:
Truist Securities BioPhar...
Adicet Bio
Do., 31.10.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024.
Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qual...
Adicet Bio
Mi., 16.10.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amendment to the Company’s Investigational New Drug (IND) application to evaluate ADI-001 in...
Adicet Bio
Mo., 30.09.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024.
Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-q...
Adicet Bio
Mo., 30.09.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer con...
Adicet Bio
Mo., 30.09.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.
“The favorable safety profile, cellular kinetics and B ce...
Adicet Bio
Do., 19.09.2024
Adicet Bio
US0070021086
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for ...
Adicet Bio
Informationen zu Product Placements
